Scientists engineered IFN-γ-resistant CD28 CAR-T cells that show increased survival and heightened anti-tumor activity in solid tumor models. This breakthrough overcomes a key limitation in CAR-T therapy for solid cancers by reducing activation-induced cell death, potentially improving clinical outcomes for patients with difficult-to-treat tumors.